D-环丝氨酸：精神分裂症学习和神经可塑性中的作用不断演变。
D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.
机构信息
Nathan Kline Psychiatric Research Institute and New York University Langone Medical Center, New York, NY, USA.
出版信息
Schizophr Bull. 2012 Sep;38(5):936-41. doi: 10.1093/schbul/sbs012. Epub 2012 Feb 23.
Abstract
As a partial agonist at the glycine site of the NMDA receptor, D-cycloserine (DCS) has been viewed as lacking potency to fully test the NMDA receptor hypofunction theory of schizophrenia. However, findings of full agonist activity at a subset of NMDA receptors that may have particular relevance to schizophrenia, plus a growing body of evidence demonstrating enhancement of learning and neuroplasticity in animal models, suggest novel therapeutic strategies with DCS in schizophrenia. Preliminary studies with once-weekly administration have supported this potential new role for DCS in schizophrenia by demonstrating benefit for negative symptoms, memory consolidation, and facilitation of cognitive behavioral therapy for delusions.
摘要
作为 NMDA 受体甘氨酸位点的部分激动剂，D-环丝氨酸（DCS）被认为缺乏效力来充分检验精神分裂症的 NMDA 受体功能低下理论。然而，在一组可能与精神分裂症特别相关的 NMDA 受体上发现了完全激动剂活性，加上越来越多的证据表明在动物模型中增强学习和神经可塑性，这表明 DCS 在精神分裂症中有新的治疗策略。每周一次给药的初步研究支持了 DCS 在精神分裂症中的这一潜在新作用，表明它对阴性症状、记忆巩固和促进妄想的认知行为疗法有益。
相似文献
1
D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.D-环丝氨酸：精神分裂症学习和神经可塑性中的作用不断演变。
Schizophr Bull. 2012 Sep;38(5):936-41. doi: 10.1093/schbul/sbs012. Epub 2012 Feb 23.
2
D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.D-环丝氨酸治疗精神分裂症：通过增强可塑性改善临床结局的新策略。
Curr Neuropharmacol. 2017;15(1):21-34. doi: 10.2174/1570159x14666160225154812.
3
Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine.增强 N-甲基-D-天冬氨酸受体信号对精神分裂症工作记忆和经验依赖性可塑性的影响：使用急性 d-环丝氨酸的探索性研究。
Schizophr Bull. 2017 Sep 1;43(5):1123-1133. doi: 10.1093/schbul/sbw193.
4
The Therapeutic Role of d-Cycloserine in Schizophrenia.D-环丝氨酸在精神分裂症中的治疗作用。
Adv Pharmacol. 2016;76:39-66. doi: 10.1016/bs.apha.2016.02.001. Epub 2016 Mar 11.
5
Effects of D-cycloserine on negative symptoms in schizophrenia.D-环丝氨酸对精神分裂症阴性症状的影响。
Schizophr Res. 2004 Dec 1;71(2-3):239-48. doi: 10.1016/j.schres.2004.03.013.
6
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy.D-环丝氨酸与恐惧消退及暴露疗法促进作用的荟萃分析。
Biol Psychiatry. 2008 Jun 15;63(12):1118-26. doi: 10.1016/j.biopsych.2008.01.012. Epub 2008 Mar 7.
7
Glycine agonists: what can they teach us about schizophrenia?甘氨酸激动剂：它们能让我们对精神分裂症有哪些了解？
Arch Gen Psychiatry. 1999 Jan;56(1):13-7. doi: 10.1001/archpsyc.56.1.13.
8
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.甘氨酸和D-环丝氨酸对精神分裂症持续性阴性症状的比较效果：一项回顾性分析。
Schizophr Res. 2004 Feb 1;66(2-3):89-96. doi: 10.1016/S0920-9964(03)00129-4.
9
D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.在抗精神病药物基础上加用D-环丝氨酸时，慢性精神分裂症患者的阳性症状会增加：一项双盲、平行、安慰剂对照研究。
Neuropsychopharmacology. 1999 Aug;21(2):203-10. doi: 10.1016/S0893-133X(99)00014-7.
10
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.一项针对精神分裂症患者，在传统抗精神病药物基础上加用D-环丝氨酸的安慰剂对照试验。
Arch Gen Psychiatry. 1999 Jan;56(1):21-7. doi: 10.1001/archpsyc.56.1.21.
引用本文的文献
1
Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration.裸盖菇素-N-甲基-D-天冬氨酸受体调节剂给药的协同行为和神经可塑性效应。
Transl Psychiatry. 2025 Jun 13;15(1):200. doi: 10.1038/s41398-025-03428-x.
2
Importance of Modulating Kynurenic Acid Metabolism-Approaches for the Treatment of Dementia.调节犬尿喹啉酸代谢的重要性——痴呆症的治疗方法
Biomolecules. 2025 Jan 6;15(1):74. doi: 10.3390/biom15010074.
3
Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.NMDA 受体功能障碍在精神分裂症病理生理学和/或治疗抵抗性精神分裂症发病机制中的作用。
Biomolecules. 2024 Sep 6;14(9):1128. doi: 10.3390/biom14091128.
4
Cycloserine-Induced Insomnia and Psychosis in Multidrug-Resistant Pulmonary Tuberculosis - A Case Report.环丝氨酸诱发耐多药肺结核患者失眠及精神病——病例报告
Cureus. 2022 Dec 26;14(12):e32963. doi: 10.7759/cureus.32963. eCollection 2022 Dec.
5
A randomized pharmacological fMRI trial investigating D-cycloserine and brain plasticity mechanisms in learned pain responses.一项随机药理学 fMRI 试验，研究 D-环丝氨酸和学习性疼痛反应中的大脑可塑性机制。
Sci Rep. 2022 Nov 9;12(1):19080. doi: 10.1038/s41598-022-23769-7.
6
Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects.泽利奎斯特内尔是一种口服生物可利用的新型 NMDA 受体变构调节剂，具有快速和持续的抗抑郁样作用。
Int J Neuropsychopharmacol. 2022 Dec 12;25(12):979-991. doi: 10.1093/ijnp/pyac043.
7
Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review).精神分裂症阴性症状治疗的当前观点：一项叙述性综述（综述）
Exp Ther Med. 2021 Mar;21(3):276. doi: 10.3892/etm.2021.9707. Epub 2021 Jan 25.
8
The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder.D-环丝氨酸与安慰剂相比在自闭症谱系障碍个体的社会和沟通技能方面的有效性和不良反应。
Cochrane Database Syst Rev. 2021 Feb 14;2(2):CD013457. doi: 10.1002/14651858.CD013457.pub2.
9
Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia .关于在精神分裂症中基于神经可塑性的听觉学习的D-丝氨酸增强作用的资助报告。
J Psychiatr Brain Sci. 2020;5(4). Epub 2020 Aug 6.
10
An Ensemble Approach to Predict Schizophrenia Using Protein Data in the N-methyl-D-Aspartate Receptor (NMDAR) and Tryptophan Catabolic Pathways.一种使用N-甲基-D-天冬氨酸受体（NMDAR）和色氨酸分解代谢途径中的蛋白质数据预测精神分裂症的集成方法。
Front Bioeng Biotechnol. 2020 Jun 4;8:569. doi: 10.3389/fbioe.2020.00569. eCollection 2020.
本文引用的文献
1
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.地昔环素增强精神分裂症妄想的认知行为治疗。
Schizophr Res. 2011 Sep;131(1-3):69-74. doi: 10.1016/j.schres.2011.05.029. Epub 2011 Jun 30.
2
Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory.NR2C 敲除小鼠的行为分析显示其在条件性恐惧获得和工作记忆方面存在缺陷。
Neurobiol Learn Mem. 2011 May;95(4):404-14. doi: 10.1016/j.nlm.2011.01.008. Epub 2011 Feb 2.
3
Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors.D-环丝氨酸在 NR1/NR2C NMDA 受体上的疗效的结构决定因素。
J Neurosci. 2010 Feb 17;30(7):2741-54. doi: 10.1523/JNEUROSCI.5390-09.2010.
4
Inhibition of NMDARs in the Nucleus Reticularis of the Thalamus Produces Delta Frequency Bursting.丘脑网状核中 NMDA 受体的抑制导致 δ 频率爆发。
Front Neural Circuits. 2009 Nov 10;3:20. doi: 10.3389/neuro.04.020.2009. eCollection 2009.
5
D-cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window.D-环丝氨酸可改善创伤性脑损伤的功能预后，治疗窗较宽。
Eur J Pharmacol. 2010 Mar 10;629(1-3):25-30. doi: 10.1016/j.ejphar.2009.11.066. Epub 2009 Dec 1.
6
Does abnormal sleep impair memory consolidation in schizophrenia?异常睡眠会损害精神分裂症患者的记忆巩固吗？
Front Hum Neurosci. 2009 Sep 1;3:21. doi: 10.3389/neuro.09.021.2009. eCollection 2009.
7
Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages.慢性药物治疗精神分裂症患者的程序性学习夜间巩固减少与特定睡眠阶段有关。
J Psychiatr Res. 2010 Jan;44(2):112-20. doi: 10.1016/j.jpsychires.2009.06.011. Epub 2009 Aug 8.
8
Impairment in long-term retention of preference conditioning in schizophrenia.精神分裂症患者偏好条件反射的长期记忆受损。
Biol Psychiatry. 2009 Jun 15;65(12):1086-90. doi: 10.1016/j.biopsych.2009.01.020. Epub 2009 Feb 26.
9
Extinction memory is impaired in schizophrenia.精神分裂症患者的消退记忆受损。
Biol Psychiatry. 2009 Mar 15;65(6):455-63. doi: 10.1016/j.biopsych.2008.09.017. Epub 2008 Nov 4.
10
Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.每周一次的D-环丝氨酸对精神分裂症阴性症状和认知的影响：一项探索性研究。
Schizophr Res. 2008 Dec;106(2-3):320-7. doi: 10.1016/j.schres.2008.08.012. Epub 2008 Sep 16.
Zotero 插件